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Abstract  
Aims: We evaluated the effects of patiromer, a potassium (K+)-binding polymer, in a 
prespecified analysis of hyperkalemic patients with heart failure (HF) in the OPAL-HK trial.  
Methods and results: CKD patients on RAASi with serum K+ levels ≥5.1-<6.5 mEq/L (n=243) 
received patiromer (4.2 g or 8.4 g BID initially) for 4 weeks (initial treatment phase); the primary 
efficacy endpoint was mean change in serum K+ from baseline to week 4. Eligible patients (those 
with baseline K+ ≥5.5-<6.5 mEq/L and levels ≥3.8-<5.1 mEq/L at the end of week 4) entered an 
8-week randomized withdrawal phase and randomly assigned to continue patiromer or switch to 
placebo; the primary efficacy endpoint was the between-group difference in median change in 
the serum K+ over the first 4 weeks of that phase. One hundred two patients (42%) had HF. The 
mean (±SE) change in serum K+ from baseline to week 4 was −1.06±0.05 mEq/L (95% CI, 
−1.16,−0.95; P<.001); 76% (95% CI, 69,84) achieved serum K+, 3.8 to <5.1 mEq/L. In the 
randomized withdrawal phase, the median increase in serum K+ from baseline of that phase was 
greater with placebo (n=22) than patiromer (n=27) (P<0.001); recurrent hyperkalemia (serum 
K+, ≥5.5 mEq/L) occurred in 52% on placebo and 8% on patiromer (P<0.001). Mild-to-moderate 
constipation was the most common adverse event (11%); hypokalemia occurred in 3%. 
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Conclusion: In patients with CKD and HF who were hyperkalemic on RAASi, patiromer was 
well-tolerated, decreased serum K+ and, compared with placebo, reduced recurrent 
hyperkalemia. 
Key words: chronic kidney disease, heart failure, hyperkalemia, patiromer 
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Introduction 
Renin angiotensin aldosterone system inhibitors (RAASi) have been shown to be 
effective in reducing mortality as well as hospitalizations for heart failure (HF) in patients with 
chronic HF and a reduced left ventricular ejection fraction (HFREF) and have been accorded a 
class 1 indication in international guidelines (1-6). In patients with chronic kidney disease (CKD) 
complicating their HF, renal excretion of potassium (K+) is compromised and is in part 
compensated by an increase in colonic excretion, which often is not sufficient to avoid 
hyperkalemia (7). Patients with CKD and HFREF are therefore at an increased risk of death but 
paradoxically often receive suboptimal doses of RAASi because of fear of inducing 
hyperkalemia (serum K+ >5.0 mEq/L) and its consequences, including sudden cardiac death (8-
10). While there are several options for the treatment of acute hyperkalemia, options for the 
management of chronic hyperkalemia, and thereby maintaining RAASi use in patients with HF, 
are limited. Agents that have been employed to manage persistently high potassium levels 
include diuretics (with or without sodium bicarbonate) and the potassium-binding resins, calcium 
polystyrene sulfonate (CPS) and sodium polystyrene sulfonate (SPS) (11,12). Calcium 
polystyrene sulfonate and SPS can lead to serious gastrointestinal AEs, including colonic 
necrosis and perforation (11-14), which has led to warnings in the prescribing information 
(11,12,15). Additionally, because sodium is the counter exchange ion with SPS, caution is 
advised when treating patients who cannot tolerate even small increases in sodium load (eg, 
those with severe congestive heart failure, severe hypertension, or marked edema) (11). Patients 
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with chronic HF who develop hyperkalemia therefore often have their dose of RAASi reduced or 
discontinued (8,10,16), thereby exposing them to increased cardiovascular risk. 
The active moiety of patiromer is a nonabsorbed oral potassium-binding polymer. It acts 
primarily in the distal colon, where the concentration of free potassium is the highest, to increase 
fecal potassium excretion (17,18). Patiromer consists of smooth, spherical beads approximately 
100 μm in diameter that are insoluble, free-flowing, and that do not swell appreciably when 
mixed with water (18). The OPAL-HK study showed patiromer to be generally well tolerated 
and effective in reducing serum K+ levels in CKD patients with mild and moderate-to-severe 
hyperkalemia (serum K+ ≥5.1–<6.5 mEq/L) (17).  
We evaluated patiromer’s efficacy and safety in a prespecified analysis of OPAL HK in 
the subgroup of CKD patients with HF and compared those results to CKD patients without HF. 
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Methods 
Study population 
The OPAL-HK study has been described previously (17). In brief, eligible patients  were 
18 to 80 years of age, had stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR] of 15–
<60 mL/min/1.73m2 of body surface area), serum K+ 5.1 to <6.5 mEq/L indicative of 
hyperkalemia, and had been receiving a stable dose of ≥1RAASi for ≥28 days. Patients who 
were also on anti-hypertensive medication, loop and thiazide diuretics, or beta-blockers, were 
receiving them at stable doses for ≥28 days.  
Patients were excluded if at screening they presented with potassium-related 
electrocardiographic changes, severe gastrointestinal disorders, uncontrolled or unstable 
arrhythmias or clinically significant ventricular arrhythmias, type 1 diabetes, New York Heart 
Association (NYHA) class IV heart failure, acute coronary syndrome, or confirmed systolic 
blood pressure >180 mmHg or <110 mmHg, or diastolic blood pressure >110 mmHg or <60 
mmHg. Patients were also excluded if they underwent recent cardiac surgery, kidney or heart 
transplantation, had an ischemic attack or stroke within the previous 2 months, or received 
emergent treatment for type 2 diabetes or acute heart failure within the previous 3 months.  
The study (NCT01810939) was conducted in accordance with the International 
Conference on Harmonisation Guideline for Good Clinical Practice and complied with the 
Declaration of Helsinki. The study protocols were reviewed and approved by institutional review 
boards and patients provided written informed consent. 
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Study protocol 
This study was carried out in 2 parts—an initial treatment phase and a randomized 
withdrawal phase. The initial treatment phase was a 4-week, single-group, single-blind 
assessment of patiromer in patients with CKD taking RAASi. At the beginning of this phase, 
patients were assigned 1 of 2 patiromer doses based on their screening serum K+ levels. Patients 
with mild hyperkalemia (serum K+ 5.1–<5.5 mEq/L) received 4.2 g of patiromer twice daily; 
patients with moderate to severe hyperkalemia (serum K+ 5.5–<6.5 mEq/L) received 8.4 g of 
patiromer twice daily. Patiromer was administered as an oral suspension in 40 to 120 mL of 
water, depending on dose, with breakfast and dinner. Subsequent doses were adjusted to reach 
and maintain target serum K+ levels based on a prespecified treatment algorithm (Supplementary 
Table 1). The target serum K+ levels were conservative to avoid hypokalemia. The RAASi dose 
was not adjusted to facilitate interpretation of primary study endpoints during the initial 
treatment phase. Patients discontinued RAASi and their participation in the study if their serum 
K+ was ≥6.5 mEq/L during the initial treatment phase.  
Following the initial treatment phase was a randomized withdrawal phase – an 8-week 
single-blind, placebo-controlled, parallel group assessment of patiromer withdrawal. Patients 
who completed the initial treatment phase were eligible to start the randomized withdrawal phase 
if they had moderate to severe hyperkalemia (serum K+ level of 5.5–<6.5 mEq/L) at baseline of 
the initial treatment phase and were normokalemic (serum K+ level within target range of 3.8–
<5.1 mEq/L) at week 4 of the initial treatment phase (baseline of the randomized withdrawal 
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phase). Patients were eligible for continuation to the randomized withdrawal phase if they were 
still taking patiromer and at least one RAASi. Eligible patients were randomized in a single-blind 
manner to either continue patiromer at the daily dose they were receiving at week 4 of the initial 
treatment phase or to switch to placebo, in a 1:1 ratio. The randomization was performed 
centrally and stratified based on the presence of type 2 diabetes as well as baseline serum K+ 
(moderate [5.5–<5.8 mEq/L] vs severe [≥5.8 mEq/L] hyperkalemia).  
Use of RAASi and recurrence of hyperkalemia were monitored during the randomized 
withdrawal phase. Hyperkalemia was defined as a serum K+ measurement ≥5.5 mEq/L during 
the first 4 weeks of the randomized withdrawal phase, and ≥5.1 mEq/L during the last 4 weeks of 
this phase. Recurrences of hyperkalemia were managed with a pre-specified treatment algorithm 
(Supplementary Table 2) either by increasing the patiromer dose (patiromer group) or by RAASi 
modification (placebo group) at the time of the first occurrence of hyperkalemia. Subsequent 
occurrences required RAASi discontinuation. Neither of these interventions was to be used 
during the first 4 weeks of the randomized withdrawal phase (unless serum K+ reached ≥5.5 
mEq/L) to facilitate the interpretation of the primary efficacy endpoint. 
Serum K+ levels were measured at local and central laboratories at baseline, day 3, and 
weekly throughout both parts of the study. Safety data were recorded at each of these visits. 
During the study, site staff counseled subjects to restrict foods high in potassium content 
(>250 mg/100 g) and to target their potassium intake to ≤2 to 3 g/day (approximately 50–75 
mEq/d). Up to 3 safety follow-up visits occurred within 1 to 2 weeks after discontinuation of 
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patiromer or placebo (including in patients who withdrew from the study or did not qualify for 
the randomized withdrawal phase) to monitor adverse event (AE) occurrence and serum K+ 
levels.  
Clinical endpoints 
The primary efficacy endpoint of the treatment phase was the mean change in serum K+ 
level from baseline to week 4 in patients who received ≥1 dose of patiromer and had at least 1 K+ 
measurement after day 3. The secondary endpoint was the proportion of patients whose serum 
K+ was within target range (3.8–<5.1 mEq/L) at week 4. The primary efficacy endpoint of the 
randomized withdrawal phase was the difference between the patiromer and placebo groups in 
the median change in serum K+ from baseline to either week 4—if serum K+ stayed in target 
range—or the earliest visit when serum K+ was outside that range. The secondary endpoints were 
the proportions of patients with a recurrence of hyperkalemia according to 2 definitions: serum 
K+ of ≥5.1 or ≥5.5 mEq/L. An exploratory efficacy endpoint of the randomized withdrawal phase 
was the proportion of patients requiring an intervention to manage a recurrence of hyperkalemia 
(ie, an increase of the patiromer dose [patiromer group] or RAASi dose reduction [placebo 
group] at the first occurrence of hyperkalemia; RAASi discontinuation at subsequent occurrences 
[both treatment groups]). Adverse events were monitored and recorded during both parts of the 
study and for up to 2 weeks after discontinuation from the study. 
Statistical analysis 
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 The mean change in serum K+ (primary endpoint) and the associated 95% confidence 
interval (CI) were estimated using a longitudinal repeated measures model of the centrally 
measured, weekly postbaseline serum K+ values. Consequently, only patients with at least 1 
weekly postbaseline measurement were included in the analyses.  For the subgroups defined by 
presence or absence of heart failure (HF), the model used 1 binary covariate (presence of type 2 
diabetes) and 1 continuous covariate (baseline serum K+). Patients were included in the HF 
subgroup based on a history of HF—per the investigator’s judgment—which included NYHA 
class, date of diagnosis (if known), and diagnosis of systolic or diastolic dysfunction (if 
determined). 
To assess the primary efficacy endpoint of the randomized withdrawal phase, changes in 
serum K+ from baseline in placebo and patiromer groups were compared using an analysis of 
variance of rank-transformed data. All patients randomized to enter the withdrawal phase were 
included in these analyses. The between-group difference in median serum K+ change from 
baseline and the associated 95% CI were calculated using a Hodges-Lehmann estimator. The 
comparison of the treatment groups used rank of change carried forward to account for and 
include patients who discontinued study drug prior to week 4 of the randomized withdrawal 
phase. For both secondary endpoint calculations, proportions of patients in the 2 treatment 
groups were compared using a Mantel-Haenszel test with baseline strata. The analyses for the 
subgroups defined by the presence or absence of heart failure did not include any adjustment for 
multiplicity. A more detailed description of the statistical analysis methods is provided in the 
primary publication describing the overall results of the OPAL-HK study (17). 
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With 240 patients enrolled, this provided more than 99% power to detect a mean change 
from baseline in serum K+ of at least 0.3 mEq/L. This calculation was based on a 2-sided, 1-
sample, paired t-test, significance level of α = 0.05, and the assumption of a standard deviation of 
0.55. SAS Version 9.2 was utilized for statistical analyses.  
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Results 
Patients 
A total of 243 patients with CKD were enrolled in the initial treatment phase, 102 (42%) 
with HF and 141 (58%) without HF (Table 1). Of the patients with HF, 39 (38%) entered the 
study with mild and 63 (62%) with moderate-to-severe hyperkalemia; of the patients without HF, 
53 (38%) had mild and 88 (62%) had moderate-to-severe hyperkalemia. All patients received at 
least 1 dose of patiromer. 
A total of 91 (89%) patients with HF completed the initial treatment phase. Of those, 42 
patients (46%) were not eligible to continue to the randomized withdrawal phase. The most 
common reason for ineligibility was a centrally measured baseline serum K+ of <5.5 mEq/L (40 
patients, 44%); 1 patient was ineligible solely because their serum K+ fell outside of target range 
at week 4. The remaining 49 patients with HF (54%) eligible for the randomized withdrawal 
phase were randomly assigned either to continue patiromer (27 patients) or to switch to placebo 
(22 patients). A total of 12 patients with HF discontinued the randomized withdrawal phase 
prematurely – 5 (19%) patients in the patiromer group and 7 (32%) patients in the placebo group. 
Most of the discontinuations were due to an elevated serum K+ that met the pre-specified 
withdrawal criteria (5 patients with HF [23%] in the placebo and 0 patients with HF in the 
patiromer group). Comprehensive disposition information for patients with and without HF can 
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be found in Supplementary Figure 1 (initial treatment phase) and Figure 2 (randomized 
withdrawal phase).   
At the start of the trial, the proportion of HF patients with stage 3 and stage 4/5 CKD, 
respectively, was 47% and 44%; in patients without HF, the corresponding proportions were 
46% and 45%. In patients with and without HF, 9% had stage 2 CKD based on central laboratory 
eGFR measurements and were included in the study because they had met entry criteria on the 
basis of eGFR measurements obtained at local laboratories. The mean serum K+ (±SD) at 
baseline was 5.6 ±0.6 mEq/L in patients with HF and 5.5 ±0.4 mEq/L in patients without HF.  
Efficacy 
Initial treatment phase 
The mean (±SE) change in serum K+ from baseline to week 4 in patients with HF (100 
patients who had at least 1 serum K+ measurement after day 3) was −1.06 ± 0.05 mEq/L (95% 
CI, −1.16, −0.95, P <.001, Figure 1a). The mean (±SE) change in serum K+ from baseline to 
week 4 in HF patients with mild HK (n = 38) was −0.74 ± 0.08 mEq/L (95% CI, −0.91, −0.57), 
and for patients with HF with moderate-to-severe HK (n = 62) the change from baseline was 
−1.26 ± 0.07 mEq/L (95% CI, −1.40, −1.12). Figure 1b shows the observed mean serum K+ over 
time. By the end of the 4-week initial treatment phase, 76% of patients with HF achieved a 
serum K+ in the target range (3.8–<5.1 mEq/L) (95% CI, 69, 84). The primary and secondary 
efficacy endpoints were similar in patients without HF (Figure 1). The mean daily dose of 
patiromer received over the 4-week initial treatment phase was 17.8 g for patients with HF and 
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18.4 g for those without HF, with a similar mean number of dose adjustments in each subgroup 
(0.8 and 0.9, respectively). 
 
Randomized withdrawal phase 
At baseline of the randomized withdrawal phase (week 4 of the initial treatment phase), 
which included only those patients whose serum K+ was controlled during the initial treatment 
phase, mean serum K+ was 4.52 mEq/L in patients with HF randomized to patiromer and 4.56 
mEq/L in patients with HF randomized to placebo. The estimated median change in serum K+ 
from baseline to week 4 of the randomized withdrawal phase was 0.74 mEq/L for patients with 
HF taking placebo and 0.10 mEq/L for those taking patiromer, for a between-group difference of 
0.64 mEq/L (95% CI, 0.29, 0.99; P<.001; Figure 2).  
In patients with HF, 52% (95% CI, 30–74) of those randomized to placebo compared 
with 8% (95% CI, 1–25) of those randomized to patiromer had at least 1 serum K+ of ≥5.5mEq/L 
during the 8-week randomized withdrawal phase (P <.001 for placebo-patiromer group 
difference). A total of 95% (95% CI, 77, >99) of patients with HF randomized to placebo and 
36% (95% CI, 19, 57) of those randomized to patiromer had at least 1 serum K+ of ≥5.1 mEq/L 
(P <.001). Figure 3 shows the time to hyperkalemia (serum K+ ≥5.1 mEq/L and ≥5.5 mEq/L) 
recurrence in patients with HF, time to hyperkalemia in patients without HF can be found in 
Supplementary Figure 3.  
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In a prespecified exploratory analysis, 13 (59%) patients with HF taking placebo 
compared with 3 (11%) patients taking patiromer required an intervention to manage their 
hyperkalemia recurrence; by the end of the randomized withdrawal phase, 55% of HF patients on 
placebo and 100% of HF patients on patiromer were still receiving RAASi. Figure 4 shows the 
time to the discontinuation of RAASi. Results were similar in patients without HF (Figures 2-4).  
Safety 
During the initial treatment phase and its follow-up period, 41% of patients with HF and 
51% of patients without HF reported at least 1 AE (Supplementary Table 3A). The most 
common AEs that occurred during the initial treatment phase are shown in Table 2. The majority 
of AEs were gastrointestinal. None of the gastrointestinal events that occurred in this phase were 
severe. Adverse events that led to patiromer discontinuation occurred in 7 (7%) patients with HF 
and 8 (6%) patients without HF. Three patients (2 with HF and 1 without HF) experienced 
nonfatal serious AEs during the initial treatment phase; the investigators did not consider the 
events related to patiromer. 
The proportion of patients with and without HF experiencing at least 1 AE during the 8-
week randomized withdrawal phase and its follow-up period was similar between the placebo 
and patiromer groups (HF, 64% and 56%, respectively; non-HF, 40% and 39%; Table 3). The 
most common gastrointestinal AEs reported in the patiromer group during this phase of the study 
were diarrhea (HF, 7%; non-HF, 0%) and nausea (HF, 7%; 0% non-HF), all mild or moderate. 
Cardiac disorders as a class were reported as AEs in 8% of HF and 7% of non-HF patients during 
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the treatment phase; all individual cardiac AEs occurred in 2 or fewer HF patients in either 
phase. One HF patient experienced worsening of HF in the treatment phase. In non-HF patients, 
left ventricular hypertrophy was reported in 6 (4%) patients and first-degree atrioventricular 
block was reported in 3 (2%) patients in the treatment phase; all other individual cardiac AEs 
occurred in 2 or fewer non-HF patients in either phase. Study drug discontinuation due to AEs 
occurred in 2 HF patients (1 [5%] taking placebo and 1 [4%] taking patiromer), and in none of 
the patients without HF.  
Two patients with HF had at least 1 serious AE during the treatment phase. In 1 HF 
patient, the serious AE was atrial fibrillation leading to hospitalization. However, the patient had 
a prior medical history of atrial fibrillation and this serious event was deemed not related to 
patiromer, per the investigator. The other serious AEs occurring during the treatment phase, all 
of which occurred in the other HF patient, are listed in Supplementary Table 3B. One HF patient 
on placebo had a serious AE during the withdrawal phase (mesenteric vessel thrombosis leading 
to death). None of the serious AEs (in either phase) were considered related to patiromer by the 
investigator.  
During the initial treatment phase and its follow-up period, hypokalemia (serum K+ <3.5 
mEq/L) occurred in 3% of patients with and without HF. These patients had serum K+ in range 
of 3.2 to 3.4 mEq/L; hypokalemia was most often transient after patiromer dose adjustment. 
During the randomized withdrawal phase and its follow-up period, hypokalemia requiring 
withdrawal from the study (serum K+ <3.8 mEq/L) occurred in 7% and 4% of patients with and 
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without HF taking patiromer and in none of the patients with HF and one (3%) patient without 
HF taking placebo. 
The mean serum magnesium level remained within normal range throughout both phases 
of the trial in patients with and without HF. Small mean decreases in serum magnesium were 
observed at the end of the initial treatment phase in patients with HF (−0.20 mg/dL [−0.16 
mEq/L]) and without HF (−0.16 mg/dL [−0.13 mEq/L]), with no apparent dose effect. At the end 
of the randomized withdrawal phase, a small mean increase from baseline was observed in serum 
magnesium in placebo patients with HF (+0.19 mEq/L) and without HF (+0.05 mEq/L). There 
was no significant change in serum magnesium levels in patiromer patients with and without HF 
during the randomized withdrawal phase. A serum magnesium level of <1.4 mg/dL was 
observed in 4 HF patients and 3 non-HF patients during the initial treatment phase. During the 
randomized withdrawal phase, no patient (with or without HF) had a serum magnesium level of 
<1.4 mg/dL.  No patient (with or without HF) had serum magnesium levels <1.2 mg/dL during 
either phase of the study. Magnesium replacement therapy was prescribed in 9 patients (3 with 
HF and 6 patients without HF) taking patiromer during the initial treatment phase. No clinically 
relevant changes in renal function or in levels of serum calcium, fluoride, or other electrolytes 
(e.g., bicarbonate) were observed in either phase of the study. Two patients in the initial 
treatment phase (1 with HF and 1 without HF) and 1 patient without HF on patiromer in the 
randomized withdrawal phase had electrocardiographic changes consistent with hyperkalemia; 
none had changes consistent with hypokalemia. No clinically relevant changes in renal function 
were observed (Supplementary Table 4).  
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Discussion  
The results of the present pre-specified analysis of the OPAL-HK trial show that patiromer 
reduced mean serum K+ to within the normal range in patents with HF. Additionally, compared 
with placebo, patiromer reduced the percentage of patients with recurrent HK and importantly, 
there were no differences in patients with and without HF in regard to these effects of patiromer. 
Mean serum K+ level was reduced from 5.6 to <5.0 mEq/L in patients with HF during the initial 
treatment phase of the study, and 76% of patients with HF achieved normokalemia. Conversely, 
in the randomized withdrawal phase only 8% of patients on patiromer developed recurrent 
hyperkalemia (when defined as serum K+ ≥5.5 mEq/L) compared with 52% on placebo, allowing 
significantly more patients to remain on guideline-recommended RAASi. This has important 
implications for patients with HF since RAASi including MRAs have been shown to reduce 
mortality in patients with HFREF (1-6). Despite the proven efficacy of RAASi and their class 1 
indication in guidelines for patients with HFREF, many clinicians have avoided their use, 
especially MRAs, because of the fear of inducing hyperkalemia (8,10). In those patients with HF 
in whom MRAs are initiated, they are often discontinued during the first several months due to 
an increase in serum K+ or worsening renal function (9,19-21). While many clinicians consider a 
serum K+ of ≥5.5 mEq/L as indicative of hyperkalemia and an increased risk for sudden cardiac 
death, increasing evidence indicates that in patients with HF and CKD a serum K+ of >5.0 
mEq/L is associated with an increase in cardiovascular risk (22). Recurrent hyperkalemia when 
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defined by serum K+ ≥5.1 mEq/L occurred in 95% of placebo patients with HF compared with 
36% of patiromer patients with HF. The present analysis also suggests that hyperkalemia 
occurring in a patient with HF can be relatively easily controlled with patiromer as evidenced by 
the finding that all of the HF patients on patiromer were able to be maintained on their RAASi 
during the randomized withdrawal phase despite the need for patiromer dose adjustment to 
manage hyperkalemia in 11%. Importantly, the use of patiromer in patients with HF has the 
potential to allow titration of RAASi doses to target levels and to maintain these dose levels. 
Target doses of RAASi appear to be more effective than lower doses in patients with HF as 
evidenced by the results in the HEAAL study (23).  
The tolerability and safety profile of patiromer in CKD patients both with and without HF 
in the present analysis supports the hypotheses that patiromer can be used to maintain the use of 
guideline-recommended RAASi. The proportion of patiromer patients discontinuing due to 
adverse effects was 7% while gastrointestinal intolerance, hypokalemia, and hypomagnesemia 
were easily managed. This study did not measure intracellular magnesium levels. In this study, 
no new-onset clinically significant arrhythmias were observed; therefore, it is unlikely that tissue 
magnesium levels were reduced to critically low levels.  
The relatively good tolerability and safety profile of patiromer in the present study, both 
in patients with and without HF, is supported by the findings in the recent AMETHYST-DN 
study (24) in which patiromer was administered to patients with hyperkalemia, CKD, type 2 
diabetes, hypertension, and receiving RAASi over a 1-year study period. In a study of patiromer 
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for the prevention of hyperkalemia (PEARL-HF) (25), normokalemia patients with HF with a 
history of discontinuation of a RAASi or beta adrenergic receptor due to hyperkalemia were 
randomized to patiromer or placebo and titrated to 50 mg/day of spironolactone. In that study, 
significantly fewer patients on patiromer developed hyperkalemia (serum K+ >5.5 mEq/L) 
compared with patients on placebo (7% vs 25%, P = 0.015) (25). In the subgroup of patients with 
CKD (eGFR <60 mL/min/1.73m2) in PEARL-HF, hyperkalemia developed in 7% of patients 
randomized to patiromer compared with a 39% of patients randomized to placebo (P = 0.041). 
While gastrointestinal adverse events occurred more frequently with patiromer than with placebo 
(21% vs 6%) they were mostly mild-to-moderate in severity, and similar proportions of patients 
in each group discontinued due to adverse events (25). 
There are limitations to the study. No placebo or active control was used in the initial treatment 
phase of this study, since it was considered unethical to allow patients with hyperkalemia to 
remain untreated. Although the withdrawal phase was randomized, it was not blinded to the 
investigators. The sponsor provided treatment algorithms to minimize bias and to standardize 
interventions when hyperkalemia or hypokalemia occurred. However, it was possible that 
changes in treatment regimen implemented by the investigator in response to hyperkalemia or 
hypokalemia may have indicated treatment assignment to the patient. The higher proportion of 
patiromer patients still receiving RAASi at the end of the withdrawal phase may have been due 
partly to the treatment algorithm, which allowed investigators to increase the dose of patiromer 
at the first occurrence of hyperkalemia in the patiromer group. The estimates for mean change 
from baseline in serum K+ during the initial treatment phase used only weekly postbaseline 
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measurements (ie, 2 HF patients with postbaseline measurements only at day 3 were excluded 
from the analysis). Since day 3 is not included in the model, our limitations include an inability 
to estimate day 3 from the repeated measures model. Instead, day 3 was estimated separately 
using an analysis of variance model with the presence of type 2 diabetes included as a binary 
covariate and baseline serum potassium as a continuous covariate. In the withdrawal phase, the 
comparison of the treatment groups used rank of change carried forward to account for and 
include patients who discontinued study drug prior to week 4 because of hyper- or hypokalemia. 
Missing serum K+ values of patients who discontinued study drug prior to week 4 for other 
reasons were imputed using multiple imputation. Patients were included in the HF subgroup 
based on a history of HF per the investigator’s judgment, therefore inaccuracies in assessing the 
differences between the groups with and without HF may have occurred because no specific 
instructions for HF diagnosis were provided. During the study, a low proportion of patients 
received concomitant aldosterone antagonist therapy, potentially because these agents are 
contraindicated in patients with hyperkalemia or with reduced renal function (eGFR <30 
mL/min/1.73 m2) (26,27). While this may limit the conclusions that can be drawn regarding the 
effect of patiromer in CKD patients with HF receiving aldosterone antagonists, the PEARL-HF 
study previously demonstrated that patiromer prevented hyperkalemia in HF patients with 
normal serum potassium levels receiving spironolactone (25). 
In conclusion, the efficacy and safety profile of patiromer demonstrated in the present 
analysis and in the AMETHYST-DN and PEARL-HF studies (24,25) suggests that patiromer 
may have an important role in initiating and maintaining RAASi in patients with CKD and HF, 
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with the potential for consequent reduction in cardiovascular death in these high risk patients. 
Further adequately powered prospective randomized studies will be required to evaluate this 
hypothesis and to determine the cost-effectiveness of this strategy. 
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Figure Legends 
Figure 1: Serum Potassium Levels over Time during the Treatment Phase 
Figure 2: Effect of Patiromer on Serum K+ in Patients With and Without Heart Failure During 
the Randomized Withdrawal Phase 
Figure 3: Time to First Recurrence of Hyperkalemia in Patients With Heart Failure During the 
Randomized Withdrawal Phase  
Figure 4: Proportion of Patients Discontinuing RAAS inhibitor Therapy during the Randomized 
Withdrawal Phase 
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Tables 
Table 1. Baseline Demographics and Clinical Characteristics 
Characteristic 
Heart Failure 
N=102 
No Heart Failure 
N=141 
 Male, n (%) 56 (55%) 84 (60%) 
Age (yr), mean (SD) 67.4 (8.6) 61.9 (11.1) 
White, n (%) 102 (100%) 137 (97%) 
eGFR (mL/min/1.73m
2
), n (%) 
  
60 to ≤90 [Stage 2] 9 (9%) 13 (9%) 
45 to <60 [Stage 3A] 20 (20%) 29 (21%) 
30 to <45 [Stage 3B] 28 (27%) 35 (25%) 
< 30 [Stage 4/5] 45 (44%) 64 (45%) 
Serum K
+
 (mEq/L), mean (SD) 5.6 (0.6) 5.5 (0.4) 
Type 2 diabetes, n (%) 55 (54%) 84 (60%) 
Time since T2DM diagnosis (yr), mean (SD) 12.0 (9.9) 14.0 (8.9) 
NYHA HF Class, n (%) 
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I 19 (19%) NA 
II 66 (65%) NA 
III 17 (17%) NA 
Myocardial infarction, n (%) 33 (32%) 27 (19%) 
Hypertension, n (%) 97 (95%) 139 (99%) 
RAASi medication, n (%) 102 (100%) 141 (100%) 
ACE inhibitor 70 (69%) 100 (71%) 
ARB 37 (36%) 55 (39%) 
Aldosterone antagonist  20 (20%) 2 (1%) 
Renin inhibitor 2 (2%) 0 
Dual RAASi blockade*, n (%) 25 (25%) 16 (11%) 
On maximal RAASi dose
†
, n (%) 42 (41%) 64 (45%) 
Other concomitant medication for HF 
  
Beta blocker 60 (59%) 68 (48%) 
Thiazide 27 (26%) 43 (30%) 
Loop 44 (43%) 33 (23%) 
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*Any combination of two or more of the following: ACE inhibitor, ARB, aldosterone antagonist, 
renin inhibitor. 
†As judged of the investigator in accordance with local standards of care.
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Table 2. Adverse Events Occurring in at Least 3% of Patients with and without HF during the 
Initial Treatment Phase and through the Safety Follow-up Period for that Phase* 
 
 
 
Heart Failure 
N = 102 
No Heart Failure 
N = 141 
No. of Patients (%) 
≥ 1 Adverse event 42 (41%) 72 (51%) 
Constipation 11 (11%) 15 (11%) 
Diarrhea 4 (4%) 4 (3%) 
Nausea 1 (1%) 7 (5%) 
Hypomagnesemia 3 (3%) 5 (4%) 
Anemia 4 (4%) 3 (2%) 
Chronic renal failure 1 (1%) 6 (4%) 
Hyperkalemia 3 (3%) 3 (2%) 
Left ventricular hypertrophy 0 6 (4%) 
Dyslipidemia 0 4 (3%) 
≥ 1 Serious adverse event 2 (2%) 1 (1%) 
This article is protected by copyright. All rights reserved.
 35 
*The safety follow-up period was 1 to 2 weeks after discontinuation of the study drug in the 
initial treatment phase. Supplementary Table 3A shows adverse events that occurred in at least 2 
patients with or without HF in each dose group and Supplementary Table 3B shows all serious 
adverse events. 
Table 3. Adverse Events Occurring in at Least 2 Patients in the Patiromer Group Regardless of 
HF diagnosis during the Randomized Withdrawal Phase and through the Safety Follow-up 
Period for That Phase* 
 
Heart Failure No Heart Failure 
Placebo  
(N = 22) 
Patiromer  
(N = 27) 
Placebo  
(N = 30) 
Patiromer  
(N = 28) 
 No. of Patients (%) No. of Patients (%) 
≥1 Adverse event 14 (64%) 15 (56%) 12 (40%) 11 (39%) 
Headache 3 (14%) 1 (4%) 1 (3%) 1 (4%) 
Supraventricular 
extrasystoles 
1 (5%) 1 (4%) 0 1 (4%) 
Diarrhea 0 2 (7%) 0 0 
Nausea 0 2 (7%) 0 0 
Constipation 0 1 (4%) 0 1 (4%) 
≥1 Serious adverse event 1† (5%) 0 0 0 
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*The safety follow-up period was 1 to 2 weeks after discontinuations of the study drug.  
†Mesenteric vessel thrombosis leading to death occurred in one patient. 
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